-
Mashup Score: 1Please wait whilst we redirect you - 1 year(s) ago
About ScienceDirectRemote accessShopping cartAdvertiseContact and supportTerms and conditionsPrivacy policyWe use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies.Copyright © 2023 Elsevier B.V. or its licensors or contributors. ScienceDirect® is a registered trademark of Elsevier B.V.ScienceDirect® is a registered trademark…
Source: www.sciencedirect.comCategories: Latest Headlines, Oncologists2Tweet
-
Mashup Score: 0Please wait whilst we redirect you - 1 year(s) ago
About ScienceDirectRemote accessShopping cartAdvertiseContact and supportTerms and conditionsPrivacy policyWe use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies.Copyright © 2023 Elsevier B.V. or its licensors or contributors. ScienceDirect® is a registered trademark of Elsevier B.V.ScienceDirect® is a registered trademark…
Source: www.sciencedirect.comCategories: Hem/Oncs, Latest HeadlinesTweet-
APCCC 2022 report now available free online till end of May. #APCCC22 @Silke_Gillessen @AOmlin https://t.co/WfOXMTZQkx
-
-
Mashup Score: 0What is the Evidence of MDT in Synchronous vs Metachronous mHSPC? APCCC 2022 Presentation - Daniel Spratt - 1 year(s) ago
At the 2022 Advanced Prostate Cancer Consensus Conference (APCCC), Daniel Spratt presents the evidence for metastasis directed therapy (MDT) in patients with synchronous and metachronous metastatic hormone sensitive prostate cancer (mHSPC). Biographies: Daniel Spratt, MD, Vincent K. Smith Chair in Radiation Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
What is the evidence of MDT in synchronous vs metachronous #mHSPC? #APCCC22 presentation by @DrSpratticus @caseccc. #WatchNow on UroToday > https://t.co/lHrqEcJap7 @APCCC_Lugano https://t.co/qrJTpyCUGV
-
-
Mashup Score: 0Are There Predictors for Successful Treatment of Oligometastatic Prostate Cancer? APCCC 2022 Presentation - Piet Ost - 1 year(s) ago
At the 2022 Advanced Prostate Cancer Consensus Conference (APCCC), Piet Ost presents predictors for the successful treatment of patients with oligometastatic and oligoprogressive prostate cancer, Biographies: Piet Ost, MD, PhD, associate professor at Ghent University, Ghent, Belgium, and radiation oncologist at the Iridium Network, Antwerp, Belgium Related Content: APCCC 2022: Are There…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Are there predictors for successful treatment of oligometastatic #ProstateCancer? #APCCC22 presentation by @piet_ost @uzgent. #WatchNow on UroToday > https://t.co/10XdBWSKpy @APCCC_Lugano https://t.co/xZ1LSFRkfg
-
-
Mashup Score: 2What is the Evidence of MDT in Synchronous vs Metachronous mHSPC? APCCC 2022 Presentation - Daniel Spratt - 1 year(s) ago
At the 2022 Advanced Prostate Cancer Consensus Conference (APCCC), Daniel Spratt presents the evidence for metastasis directed therapy (MDT) in patients with synchronous and metachronous metastatic hormone sensitive prostate cancer (mHSPC). Biographies: Daniel Spratt, MD, Vincent K. Smith Chair in Radiation Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
What is the evidence of MDT in synchronous vs metachronous #mHSPC? #APCCC22 presentation by @DrSpratticus @caseccc. #WatchNow on UroToday > https://t.co/lHrqEcJap7 @APCCC_Lugano https://t.co/g4bfL0aQbV
-
-
Mashup Score: 2Are There Predictors for Successful Treatment of Oligometastatic Prostate Cancer? APCCC 2022 Presentation - Piet Ost - 1 year(s) ago
At the 2022 Advanced Prostate Cancer Consensus Conference (APCCC), Piet Ost presents predictors for the successful treatment of patients with oligometastatic and oligoprogressive prostate cancer, Biographies: Piet Ost, MD, PhD, associate professor at Ghent University, Ghent, Belgium, and radiation oncologist at the Iridium Network, Antwerp, Belgium Related Content: APCCC 2022: Are There…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Are there predictors for successful treatment of oligometastatic #ProstateCancer? #APCCC22 presentation by @piet_ost @uzgent. #WatchNow on UroToday > https://t.co/10XdBWSKpy @APCCC_Lugano https://t.co/hUcLsNQhuQ
-
-
Mashup Score: 1Lutetium-617 - Treatment Sequencing Considerations for Metastatic Castration-Resistant Prostate Cancer - Neal Shore - 1 year(s) ago
Neal Shore joins Alicia Morgans during APCCC 2022 to discuss sequencing strategies to implement lutetium-617 for patients with metastatic castration-resistant prostate cancer (mCRPC). Drs. Shore and Morgans consider the many treatment options now available as Dr. Shore emphasizes that monotherapy should no longer be an option. Finally, important concerns about bone health and its impact on…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
Lutetium-617 - treatment sequencing considerations for #mCRPC. Neal Shore, MD, FACS @AtlanticUrology joins @CaPsurvivorship @DanaFarber to discuss sequencing strategies to implement lutetium-617. #WatchNow > https://t.co/gbal3zYrOA #APCCC22 https://t.co/RDkSOHwG8z
-
-
Mashup Score: 0The Uptake of New Treatment Options for mHSPC in Real Life -- Education, Access, Use, and Diversity APCCC 2022 Presentation - Andrew Armstrong - 1 year(s) ago
At the 2022 Advanced Prostate Cancer Consensus Conference (APCCC) Hybrid Meeting, Andrew Armstrong presents the uptake of new treatment options for mHSPC in real life, including education, access, use, and diversity. Biographies: Andrew Armstrong, MD, Professor of Medicine, Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC Related Content: APCCC 2022:…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
The uptake of new treatment options for #mHSPC in real life -- Education, access, use, and diversity. #APCCC22 presentation by @AarmstrongDuke @DukeCancer. #WatchNow on UroToday > https://t.co/xFK2nh0pjv @APCCC_Lugano @Silke_Gillessen @AOmlin https://t.co/ZnXq6fcol5
-
-
Mashup Score: 0
At the 2022 Advanced Prostate Cancer Consensus Conference (APCCC) Hybrid Meeting, Karim Fizazi presents when low-volume disease on conventional imaging becomes high-volume on next-generation imaging in mHSPC, we should treat these patients like low volume patients. Biographies: Karim Fizazi, MD, Ph.D., is a medical oncologist at Gustave Roussy, and a full professor in Oncology at the University…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
When low-volume on conventional imaging goes into high-volume on next-generation imaging in #mHSPC - treat like low-volume. #APCCC22 presentation by @fizazi_karim @GustaveRoussy. #ReadNow on UroToday > https://t.co/4IdLuLbtyd @APCCC_Lugano @Silke_Gillessen @AOmlin https://t.co/cAvlwVNFEU
-
-
Mashup Score: 0What is the Evidence of MDT in Synchronous vs Metachronous mHSPC? APCCC 2022 Presentation - Daniel Spratt - 1 year(s) ago
At the 2022 Advanced Prostate Cancer Consensus Conference (APCCC), Daniel Spratt presents the evidence for metastasis directed therapy (MDT) in patients with synchronous and metachronous metastatic hormone sensitive prostate cancer (mHSPC). Biographies: Daniel Spratt, MD, Vincent K. Smith Chair in Radiation Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University…
Source: UroTodayCategories: General Medicine News, Latest HeadlinesTweet-
What is the evidence of MDT in synchronous vs metachronous #mHSPC? #APCCC22 presentation by @DrSpratticus @caseccc. #WatchNow on UroToday > https://t.co/lHrqEcJap7 @APCCC_Lugano https://t.co/WkC7CjnoVn
-
RT @Prof_Nick_James: APCCC 2022 report now available free online till end of May. #APCCC22 @Silke_Gillessen @AOmlin https://t.co/WfOXMTZQkx